Rationale and study design of the IRENE-trial (NVALT-16): a phase II trial to evaluate iressa rechallenge in advanced NSCLC patients with an activating EGFR mutation who responded to an EGFR-TKI used as first-line or previous treatment.

J. Kuiper,D. Heideman,T. Würdinger,K. Grünberg,H. Groen,E. Smit
DOI: https://doi.org/10.1016/j.cllc.2014.07.008
IF: 4.84
Clinical Lung Cancer
Abstract:
What problem does this paper attempt to address?